new weight loss injection retatrutide Promises Big Loss, but Safety Remains a Question NEXT-GEN DRUG: An experimental weight-loss
Description
H., Renstrom, E
Amongst SGLT2-I, canagliflozin specifically has raised concerns about risk of bone fracture, although it is unclear whether an association exists with other SGLT2-I
[Google Scholar] 32.Kanda R, Hiraike H, Wada-Hiraike O, et al
The first pertained to physical health effects, with participants reporting an overall positive experience of taking the medication, finding that the improvements in weight and blood glucose control outweighed the gastrointestinal side effects
, , ,
